Potassium Chloride for Injection

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L, while the main cation outside cells is sodium ions, and the serum potassium concentration is only 3.5-5.0 mmol/L. The body mainly relies on Na+-K+ ATPase on the cell membrane to maintain the difference in K+ and Na+ concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference inside and outside the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal potassium ion concentration and concentration difference inside and outside cells are closely related to certain functions of cells, such as carbohydrate metabolism, glycogen storage and protein metabolism, excitability and conductivity of nerves and muscles including myocardium, etc.

Potassium chloride

This product is white lump or powder.

1. Treat hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, use of potassium-excreting diuretics, hypokalemic familial periodic paralysis, long-term use of glucocorticoids and hypokalemia caused by supplementation of hypertonic glucose, etc. 2. Prevent hypokalemia. When patients have potassium loss, especially if hypokalemia is harmful to patients (such as patients using digitalis drugs), preventive potassium salt supplementation is required, such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, Bartter syndrome, etc. 3. Digitalis poisoning causes frequent, multi-source premature beats or rapid arrhythmias.

Used for patients with severe hypokalemia or those who cannot take it orally. The general usage is to add 1-1.5g of potassium chloride for injection to 500ml of 5% glucose injection and drip (avoid direct intravenous drip and push injection). The dose, concentration and speed of potassium supplementation are determined according to the clinical condition, blood potassium concentration and improvement of the potassium deficiency pattern on the electrocardiogram. The potassium concentration should not exceed 3.4g/L (45mmol/L), the potassium supplementation rate should not exceed 0.75g/hour (10mmol/hour), and the daily potassium supplementation amount should be 3-4.5g (40-60mmol). When potassium deficiency in the body causes severe rapid ventricular ectopic arrhythmias, such as torsades de pointes, short bursts, recurrent multiline ventricular tachycardia, ventricular flutter and other life-threatening severe arrhythmias, the potassium salt concentration should be high (0.5%, or even

1. When the intravenous drip concentration is high, the speed is fast or the vein is thin, it is easy to stimulate the venous lining and cause pain. 2. When the drip speed is fast or there is original renal damage, attention should be paid to the occurrence of hyperkalemia. Once hyperkalemia occurs, it should be treated urgently.

1. Patients with hyperkalemia. 2. Patients with acute renal insufficiency or chronic renal insufficiency are contraindicated.

1. Adrenal glucocorticoids, especially those with more obvious mineralocorticoid effects, adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used in combination with this product, the efficacy of potassium salts will be reduced. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Non-steroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When used in combination with stored blood (containing 30mmol/L potassium for less than 10 days of storage, 65mmol/L potassium for more than 10 days of storage), potassium-containing drugs and potassium-sparing diuretics, the chance of hyperkalemia increases, especially in patients with renal damage. 5. Blood

Keep in a sealed container. The validity period is tentatively set at two years.

1.5g

Hebei Aier Haitai Pharmaceutical Co., Ltd.

• Founded in:

  2006-03-07

• Address:

  No. 219, Taishan Street, Shijiazhuang High-tech Industrial Development Zone

• Tax NO.:

  91130101785718732X

• Registered Funds:

  55.1622 million yuan

• Website:

  Log in to view

• Email:

  Log in to view